Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep M Gatell

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Science Translational Medicine|January 4, 2013
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replicationFelipe García, Nuria Climent, Alberto C Guardo, et al.
Journal of the International AIDS Society|November 14, 2014
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patientsJosep M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Immunology|April 20, 2011
The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responsesMontserrat Plana, Felipe Garcia, Laila Darwich, et al.
Plos One|December 31, 2015
Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based CohortCésar Garriga, Patricia García de Olalla, Josep M Miró, et al.
Antiviral Therapy|January 18, 2005
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis CMontserrat Laguno, Jordi Blanch, Javier Murillas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2005
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)Esteban Ribera, Carlos Azuaje, Rosa M Lopez, et al.
Journal of the International AIDS Society|October 5, 2014
Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammationBerta Torres, Alberto C Guardo, Lorna Leal, et al.
The Journal of Antimicrobial Chemotherapy|June 25, 2025
48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trialElisa de Lazzari, Silvana Di Gregorio, Jhon Rojas, et al.
Journal of Virology|January 20, 2012
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1Edurne Gallastegui, Brett Marshall, David Vidal, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|October 5, 2010
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]Josep M Llibre, Antonio Antela, José Ramón Arribas, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Science Translational Medicine|January 4, 2013
A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replicationFelipe García, Nuria Climent, Alberto C Guardo, et al.
Journal of the International AIDS Society|November 14, 2014
Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patientsJosep M Gatell, Javier O Morales-Ramirez, Debbie P Hagins, et al.
Immunology|April 20, 2011
The reconstitution of the thymus in immunosuppressed individuals restores CD4-specific cellular and humoral immune responsesMontserrat Plana, Felipe Garcia, Laila Darwich, et al.
Plos One|December 31, 2015
Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based CohortCésar Garriga, Patricia García de Olalla, Josep M Miró, et al.
Antiviral Therapy|January 18, 2005
Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis CMontserrat Laguno, Jordi Blanch, Javier Murillas, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2005
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)Esteban Ribera, Carlos Azuaje, Rosa M Lopez, et al.
Journal of the International AIDS Society|October 5, 2014
Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammationBerta Torres, Alberto C Guardo, Lorna Leal, et al.
The Journal of Antimicrobial Chemotherapy|June 25, 2025
48 Week body composition changes in persons with HIV switching to dolutegravir plus lamivudine: a planned subanalysis of the DOLAM randomized clinical trialElisa de Lazzari, Silvana Di Gregorio, Jhon Rojas, et al.
Journal of Virology|January 20, 2012
Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1Edurne Gallastegui, Brett Marshall, David Vidal, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|October 5, 2010
[Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]Josep M Llibre, Antonio Antela, José Ramón Arribas, et al.
Pageof 7